Core Insights - Bionano Genomics reported preliminary financial results for Q4 and the full year 2025, highlighting a strategic transformation towards routine users of optical genome mapping (OGM) solutions and improved financial metrics [2][3]. Financial Performance - Total revenue for Q4 2025 is projected to be between $7.8 million and $8.0 million, reflecting a year-over-year decrease of 2% to 4% [6]. - For the full year 2025, total revenue is expected to be in the range of $28.4 million to $28.6 million, indicating a decrease of 7% to 8% year-over-year [6]. - As of December 31, 2025, the company had approximately $29.6 million in cash and cash equivalents, with $10.3 million subject to restrictions [3]. Business Developments - The company established a second category I CPT code for OGM in constitutional genetic disorders and saw a 47% increase in payment determination for the existing CPT code related to hematologic malignancies [2]. - Bionano experienced significant growth in published clinical research supporting OGM as an alternative to traditional cytogenetic methods, with an increase in peer-reviewed publications and reported clinical research genomes [2]. - The company installed 9 new OGM systems in Q4 2025, contributing to a total of 387 installed systems by year-end, up from 371 at the end of 2024 [6].

Core Insights - Bionano Genomics showcased the expanding role of optical genome mapping (OGM) in genetic disease research at the ASHG conference, emphasizing its effectiveness in detecting structural variants (SVs) related to various genetic conditions [1][2][3] Group 1: Event Participation - Bionano Genomics participated in the ASHG conference held from October 14–18, 2025, in Boston, highlighting the potential of OGM in genetic research [1] - The conference featured nine studies that demonstrated OGM's ability to detect novel SVs that traditional techniques may miss, underscoring its value in complex genetic conditions [2] Group 2: Scientific Contributions - Presentations included studies on OGM's application in various conditions, such as Duchenne Muscular Dystrophy and facioscapulohumeral muscular dystrophy (FSHD), showcasing its unique capabilities [6] - The studies presented at ASHG 2025 illustrate OGM's potential to provide deeper insights into complex genetic conditions, reinforcing its transformative role in genetic research [3] Group 3: Company Mission and Offerings - Bionano aims to transform genome analysis through OGM solutions, diagnostic services, and software, catering to basic, translational, and clinical research applications [5] - The company also provides OGM-based diagnostic testing services through its subsidiary, Lineagen, Inc. [7]